FHTX:NASDAQFoghorn Therapeutics Inc. Analysis
Data as of 2026-09-25 - not real-time
$3.58
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind Foghorn Therapeutics Inc. is neutral at $3.58, with no clear ordering between short and long averages. The last 30 days have lost 44.9%. RSI sits at 22.0, which reads as oversold, and MACD momentum is bearish. Recent trading has carved out support near $3.46 and resistance around $6.24.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 220.1% above where the shares trade now. Revenue is growing at 112.7% on a -175.8% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 59.8%, a beta of 1.84 and a maximum drawdown of 49.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 220.1% above where the shares trade now. Revenue is growing at 112.7% on a -175.8% profit margin.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 59.8%, a beta of 1.84 and a maximum drawdown of 49.4%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top Market Events
Yahoo Finance1monWall Street Analysts Think Foghorn Therapeutics FHTX Could Surge 67.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- RSI at 22.0 signals oversold conditions
- Trading below the 200-day average of 5.08
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- RSI at 22.0 signals oversold conditions
- Trading below the 200-day average of 5.08
- Analyst targets imply +220.1% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- Negative profit margin of -175.8%
- Analyst targets imply +220.1% versus the current price
- Revenue growth of +112.7%
Key Metrics & Analysis
Financial Health
Revenue Growth112.70%
Profit Margin-175.78%
P/E Ratio-3.3
ROA-19.92%
P/B Ratio-2.6
Op. Cash Flow$-84241000
Free Cash Flow$-51954876
Industry P/E30.5
Technical Analysis
TrendNeutral
RSI22.0
Support$3.46
Resistance$6.24
MA 20$4.56
MA 50$5.31
MA 200$5.08
MACDBearish
VolumeIncreasing
Fear & Greed Index94.77
Valuation
Target Price$11.44
Upside/Downside220.12%
GradeFair
TypeGrowth
Risk Assessment
Beta1.84
Volatility59.76%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.